Weill Cornell Medical College Sandra & Edward Meyer Cancer Center | Strategic Alliance Partners

Prostate cancer is a highly hetero-geneous disease, with individual tumor cells having distinct genomic and pheno-typic characteristics, resulting in a great deal of variability in patients’ disease course.

Nasser Khaled Altorki, MD, discusses the results of post-hoc analyses of the phase 3 IMpower010 trial in non–small cell lung cancer.

Scott Tagawa, MD, MS, FACP, discuss the integration of targeted agents in prostate cancer.

Peter Martin, MD, discusses the importance of designing clinical trials for real-world utility in mantle cell lymphoma.

Sacituzumab govitecan-hziy, a Trop-2directed antibody-drug conjugate with an SN-38 payload, has carved out a role in the treatment landscape for patients with locally advanced or metastatic urothelial cancer following accelerated approval by the FDA.

Gail J. Roboz, MD, discusses the importance of utilizing genomic analysis to help guide treatment decisions in patients with acute myeloid leukemia.

Dr. Tagawa discusses the FDA approval of sacituzumab govitecan in urothelial cancer, key efficacy and safety data from the pivotal TROPHY-U-01 trial, and expectations for the confirmatory TROPiCS-04 trial.

Peter Martin, MD, discusses the role of maintenance therapy with rituximab in mantle cell lymphoma.

Scott T. Tagawa, MD, MS, FACP, discusses tumor targeting with radionuclides in prostate cancer.

John P. Leonard, MD, discusses the future of PI3K inhibitors in follicular lymphoma.

John P. Leonard, MD, discusses the potential for combination regimens with PI3K inhibitors in follicular lymphoma.

Peter Martin, MD, discusses the findings of a real-world analysis of clinical outcomes in mantle cell lymphoma.

Peter Martin, MD, discusses discrepancies in real-world patterns of care for patients with MCL and what can be done to overcome them.

Peter Martin, MD, discusses the rationale to evaluate real-world outcomes in mantle cell lymphoma.

Roy S. Herbst, MD, PhD, was inspired to become an oncologist during his first week as an MD/PhD candidate at Cornell University and The Rockefeller University, thanks in part to Ralph L. Nachman, MD, longtime chair of Weill Department of Medicine at Weill Cornell Medical College.

Scott T. Tagawa, MD, MS, FACP, discusses the FDA approval of sacituzumab govitecan-hziy in advanced urothelial carcinoma.

Ghaith Abu-Zeinah, MD, discusses the efficacy of interferon-alpha in polycythemia vera.

Peter Martin, MD, discusses selecting among BTK inhibitors for the treatment of patients with mantle cell lymphoma.

Ghaith Abu-Zeinah, MD, discusses utilizing interferon-alpha in patients with polycythemia vera.

Peter Martin, MD, discusses treatment considerations for patients with mantle cell lymphoma.

Peter Martin, MD, discusses the importance of developing novel therapies in mantle cell lymphoma.

Peter Martin, MD, discusses the potential role of LOXO-305 in mantle cell lymphoma.

Peter Martin, MD, discusses potential combination regimens with BTK inhibitors in mantle cell lymphoma.

As more options emerge in the mantle cell lymphoma paradigm, choosing among the agents available has become all the more challenging.

Jia Ruan, MD, PhD, discusses the future evaluation of lenalidomide plus rituximab in mantle cell lymphoma.

Jia Ruan, MD, PhD, discusses the long-term benefits of lenalidomide plus rituximab in mantle cell lymphoma.

BCLC B intermediate stage hepatocellular carcinoma, defined as patients with unresectable, liver-limited disease and preserved liver function, encompasses a broad range of patients with variable tumor size, number, and location.

Jia Ruan, MD, PhD, discusses updated results with the combination of lenalidomide and rituximab in mantle cell lymphoma.

John N. Allan, MD, discusses the safety profile of ibrutinib in high-risk chronic lymphocytic leukemia.

December 11, 2020 - Oncolytic viral therapy has been heavily investigated across oncology, but plenty of work still lies ahead to determine how this treatment approach can be applied in gastrointestinal malignancies.